Korelasi Antara Kadar Ferritin Serum dengan Procalcitonin Pada Pasien COVID-19
Downloads
Latar Belakang: Wabah Coronavirus Disease 2019 (COVID-19) disebabkan oleh Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2). Temuan laboratorium pada pasien COVID-19 yang parah melibatkan penanda inflamasi yang meningkat, termasuk feritin. Feritin adalah mediator kunci dari disregulasi imun, terutama di bawah hiperferitinemia ekstrim. Pasien COVID-19 dengan hiperferitinemia memiliki tingkat penanda inflamasi yang jauh lebih tinggi, salah satunya adalah prokalsitonin (PCT). Tujuan: Penelitian ini bertujuan untuk mengetahui hubungan kadar feritin serum dengan PCT pada pasien COVID-19. Metode: Metode penelitian ini adalah analitik korelatif. Sampel adalah data rekam medik sebanyak 463 pasien COVID-19 di RS Persahabatan periode Januari – Desember 2021. Hubungan antara kadar feritin serum dengan kadar PCT dianalisis secara statistik menggunakan uji Spearman. Hasil: Hasil penelitian ini diperoleh 240 (51,8%) pasien laki-laki dengan kelompok umur tertinggi 46-59 tahun sebanyak 160 (34,6%) pasien dan 60 tahun sebanyak 163 (35,0%) pasien. Rerata kadar feritin serum adalah 995.218 µg/L dengan kadar minimum 11,3 µg/L dan kadar maksimum 22.612,7 µg/L, sedangkan rerata kadar PCT adalah 0,3892 ng/mL dengan kadar minimum 0 ,00 ng/mL dan kadar maksimum 50,73 ng/mL. Hasil uji korelasi Spearman diperoleh nilai p 0,000 dan rho 0,573. Kesimpulan: Rumah sakit atau institusi pelayanan dapat menerapkan hasil penelitian ini dengan melakukan salah satu pemeriksaan kadar feritin serum atau PCT sambil memantau co-diagnosis pasien.
Downloads
Pangestu N. Pemeriksaan Laboratorium pada Coronavirus Disease 2019 ( COVID-19 ). 2020;7:304–19.
Velavan TP, Meyer CG. The COVID-19 epidemic. 2020;25(3):278–80.
Kumar A, Singh R, Kaur J, Pandey S, Sharma V, Thakur L, et al. Wuhan to world: the COVID-19 pandemic. Front Cell Infect Microbiol. 2021;242.
Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 cytokine storm; what we know so far. Front Immunol. 2020;1446.
WHO. Situation Report: World Health Organization. Coronavirus Dis 2019. 2022;87(February):11.
Styawan DA. Pandemi Covid-19 Dalam Perspektif Demografi. In: Seminar Nasional Official Statistics. 2020. p. 182–9.
Cortis D. On determining the age distribution of COVID-19 pandemic. Front public Heal. 2020;8:202.
Davies NG, Klepac P, Liu Y, Prem K, Jit M, Eggo RM. Age-dependent effects in the transmission and control of COVID-19 epidemics. Nat Med. 2020;26(8):1205–11.
Guo T, Shen Q, Guo W, He W, Li J, Zhang Y, et al. Clinical Characteristics of Elderly Patients with COVID-19 in Hunan Province , China : A Multicenter , Retrospective Study. 2020;410011(139):467–75.
Kyriazis M, Mikellides G, Pantelidakis H, Polycarpou M, Panayiotou B. COVID-19 Isolation and Risk of Death in Cyprus Elderly People. Front Med. 2021;1263.
Yang L, Liu S, Liu J, Zhang Z, Wan X, Huang B, et al. COVID-19: immunopathogenesis and Immunotherapeutics. Signal Transduct Target Ther. 2020;5(1):1–8.
Acosta MAT, Singer BD. Pathogenesis of COVID-19-induced ARDS: implications for an ageing population. Eur Respir J. 2020;56(3).
Lai C-C, Shih T-P, Ko W-C, Tang H-J, Hsueh P-R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924.
Mehta OP, Bhandari P, Raut A, Kacimi SEO, Huy NT. Coronavirus disease (COVID-19): comprehensive review of clinical presentation. Front Public Heal. 2021;8:582932.
Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med. 2020;58(7):1131–4.
Huang I, Pranata R, Lim MA, Oehadian A, Alisjahbana B. C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. Ther Adv Respir Dis. 2020;14:1753466620937175.
Velavan TP, Meyer CG. Mild versus severe COVID-19: laboratory markers. Int J Infect Dis. 2020;95:304–7.
Vargas M V, Rojo C C. Ferritin levels and COVID-19. Rev Panam Salud Publica/Pan Am J Public Heal. 2020;44:2019–20.
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet [Internet]. 2020;395(10229):1033–4. Available from: http://dx.doi.org/10.1016/S0140-6736(20)30628-0
Kim YS, Son A, Kim J, Kwon S Bin, Kim MH, Kim P, et al. Chaperna-mediated assembly of ferritin-based middle East respiratory syndrome-coronavirus nanoparticles. Front Immunol. 2018;9(MAY):1–20.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62.
Gilbert DN. Neglected variables in the interpretation of serum procalcitonin levels in patients with septic shock. J Infect Dis. 2021;222(Suppl 2):S96–102.
Tang J, Lin J, Zhang E, Zhong M, Luo Y, Fu Y, et al. Serum IL-6 and procalcitonin are two promising novel biomarkers for evaluating the severity of COVID-19 patients. Medicine (Baltimore). 2021;100(22).
Liu F, Li L, Xu M, Wu J, Luo D, Zhu Y, et al. Prognostic value of IL-6, CRP, and PCT in patients with COVID-19. J Clin Virol. 2020;(January).
Boenisch S, Fae P, Drexel H, Walli AK, Fraunberger P. Are circulating levels of CRP compared to IL-6 and PCT still relevant in intensive care unit patients? 1. Laboratoriumsmedizin. 2013;37(1).
Lin Z, Long F, Yang Y, Chen X, Xu L, Yang M. Serum ferritin as an independent risk factor for severity in COVID-19 patients. J Infect. 2020;81(4):647–79.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–13.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA - J Am Med Assoc. 2020;323(11):1061–9.
Li L quan, Huang T, Wang Y qing, Wang Z ping, Liang Y, Huang T bi, et al. COVID-19 patients’ clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol. 2020;92(6):577–83.
Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708–20.
Cen Y, Chen X, Shen Y, Zhang X, Lei Y, Xu C, et al. Risk factors for disease progression in patients with mild to moderate coronavirus disease 2019da multi-centre observational study. 2020;(January).
Sarvasti D. Pengaruh Gender Dan Manifestasi Kardiovaskular Pada COVID-19. Indones J Cardiol. 2020;41(2):126–32.
De Groot NG, Bontrop RE. COVID-19 pandemic: is a gender-defined dosage effect responsible for the high mortality rate among males? Springer; 2020.
Cai H. Sex difference and smoking predisposition in patients with COVID-19. Lancet Respir Med. 2020;8(4):e20.
Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect. 2020;(January).
Antezana JPE, Ferrufino NFL, Alanoca AM, Alarcón-de-la-vega G, Arnez LEA, Saavedra MAB, et al. Risk factors for mortality in patients with Coronavirus Disease 2019 ( COVID-19 ) in Bolivia : An analysis of the first 107 confirmed cases. 2020;2019:238–42.
Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. 2020;(January).
Kang S-J, Jung SI. Age-related morbidity and mortality among patients with COVID-19. Infect Chemother. 2020;52(2):154.
Vermonte P, Wicaksono TY. Karakteristik dan Persebaran COVID-19 di Indonesia : Temuan Awal. CSIS Comment DMRU-043-ID. 2020;(April):1–12.
YaÄŸcı S, Serin E, Acicbe Ö, Zeren MÄ°, Odabaşı MS. The relationship between serum erythropoietin, hepcidin, and haptoglobin levels with disease severity and other biochemical values in patients with COVIDâ€19. Int J Lab Hematol. 2021;43:142–51.
Jia F, Liu H, Kang S. NCOA4-Mediated Ferritinophagy: A Vicious Culprit in COVID-19 Pathogenesis? Front Mol Biosci. 2021;8:761793.
Singer AJ, Morley EJ, Meyers K, Fernandes R, Rowe AL, Viccellio P, et al. Cohort of four thousand four hundred four persons under investigation for COVID-19 in a New York hospital and predictors of ICU care and ventilation. Ann Emerg Med. 2020;76(4):394–404.
Fernandez FH, Valencia HS, Aponte RAB, Jimenez RC, Martin OA, Barrena C, et al. Cerebrovascular disease in patients with COVID-19: Neuroimaging, histological and clinical description. Brain. 2020;143(10):3089–103.
Taneri PE, Ochoa SAG, Llanaj E, Raguindin PF, Rojas LZ, DÃaz ZMR, et al. Anemia and iron metabolism in COVID-19: a systematic review and meta-analysis. Eur J Epidemiol. 2020;35(8):763–73.
Rosário C, Goddard GZ, Holtz EGM, D’Cruz DP, Shoenfeld Y. The Hyperferritinemic Syndrome: Macrophage activation syndrome, Still’s disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med. 2013;11(1).
Li Y, Hu Y, Yu J, Ma T. Retrospective analysis of laboratory testing in 54 patients with severe-or critical-type 2019 novel coronavirus pneumonia. Lab Investig. 2020;100(6):794–800.
Keski H. Hematological and Inflammatory Parameters to Predict the Prognosis in COVID-19. Indian J Hematol Blood Transfus [Internet]. 2021;37(4):534–42. Available from: https://doi.org/10.1007/s12288-021-01407-y
Shen Y, Cheng C, Zheng X, Jin Y, Duan G, Chen M, et al. Elevated procalcitonin is positively associated with the severity of COVID-19: A meta-analysis based on 10 cohort studies. Medicina (B Aires). 2021;57(6):594.
Wolfisberg S, Gregoriano C, Schuetz P. Procalcitonin for individualizing antibiotic treatment: an update with a focus on COVID-19. Crit Rev Clin Lab Sci. 2022;59(1):54–65.
Vijayan AL, Ravindran S, Saikant R, Lakshmi S, Kartik R. Procalcitonin: a promising diagnostic marker for sepsis and antibiotic therapy. J intensive care. 2017;5(1):1–7.
Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states : A clinical − therapeutic staging proposal. 2020;(Figure 1):3–5.
